Research Journal of Medical Sciences
ISSN: Online 1993-6095ISSN: Print 1815-9346
155
Views
13
Downloads
Abstract
Trabeculectomy is a surgical procedure performed to treat glaucoma, specifically primary open‐angle glaucoma (POAG). As subconjunctival fibrosis is found to be the common cause of bleb failure, different wound modulation agents are being tried as adjuvants to improve the long‐term success of trabeculectomy. The objective of the current investigation is to compare the efficacy of mitomycin C (MMC) and Ologen implant (Olo) in trabeculectomy in patients with POAG in eastern India. The duration of the investigation was 18 months, from November 2019 to April 2021. It was a hospital‐based prospective randomized parallel group comparison. Group A patients underwent MMC trabeculectomy, while Group B patients underwent Olo implant type 830601 trabeculectomy. The mean pre‐operative IOP for the Olo group was 34.0 (IQR: 30.75‐38.0), while for the MMC intervention group it was 36.50 (IQR: 31‐42). The difference in IOP between the two groups was insignificant (p = 0.24). On the first postoperative day, the IOP in the MMC group was 10.05±3.65 mmHg and in the Olo group it was 10.35±2.13 mmHg. Seven days after surgery, the mean IOP in the MMC group was 9.45±3.0 mmHg, while it was 11.50±2.52 mmHg in the Olo group. One month after surgery, the mean IOP in the MMC group was 11.15±4.25 mmHg, whereas it was 11.50±5.02 mmHg in the Olo group. At 3 months post‐operatively, the mean IOP in the MMC group was 12.25± 5.17 mmHg, while it was 12.70±1.84 mmHg in the Olo group. Six months after surgery, the mean IOP in the MMC group was 10.55±2.72 mmHg, whereas in the Olo group it was 13.35±2.94 mmHg. In trabeculectomy surgery on POAG eyes, the MMC and Olo implants both successfully lower intraocular pressure. Between the two groups, there was no statistical significance in the success rates.
How to cite this article:
Naresh Desinayak, Pallavi Shree and Sukhada Mishra. Trabeculectomy with Mitomycin and Ologen Implant Are Equally Effective in Reducing Intraocular Pressure in Primary Open Angle Glaucoma.
DOI: https://doi.org/10.36478/10.59218/makrjms.2023.646.650
URL: https://www.makhillpublications.co/view-article/1815-9346/10.59218/makrjms.2023.646.650